12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACH-2684: Additional Phase Ib data

Data from 30 patients with HCV genotype 1 infection in the Phase Ib portion of a 3-part, double-blind, U.S. Phase Ia/Ib trial showed that once-daily 100 mg oral ACH-2684 led to a mean maximum reduction in HCV RNA levels from baseline to day 3 of 3.36 log10 IU/mL vs. 0.68 log10 IU/mL for placebo. Additionally, once-daily 400...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >